To further demonstrate the in vivo therapeutic potentials of targeting Prmt1 in the clinically relevant setting, we transplanted MOZ-TIF2 leukemia cells carrying UbC-luciferase reporter without any pretreatment into syngeneic mice and then subjected them to AMI-408 treatment. This evidence concerns the gene PRMT1 and leukemia.